These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38091052)

  • 1. Optimal dosage of rituximab for children with Burkitt lymphoma.
    Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
    Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
    Chin Med J (Engl); 2021 Mar; 134(11):1329-1334. PubMed ID: 33734131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
    Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
    Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features and prognosis of children with Burkitt's lymphoma: an analysis of 62 cases].
    Wang YC; DU WC; Yin CY; Gong X; Li YF
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):561-565. PubMed ID: 35644197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].
    Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
    Zhonghua Er Ke Za Zhi; 2018 Aug; 56(8):605-610. PubMed ID: 30078243
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
    Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
    Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
    Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
    Ribrag V; Koscielny S; Bosq J; Leguay T; Casasnovas O; Fornecker LM; Recher C; Ghesquieres H; Morschhauser F; Girault S; Le Gouill S; Ojeda-Uribe M; Mariette C; Cornillon J; Cartron G; Verge V; Chassagne-Clément C; Dombret H; Coiffier B; Lamy T; Tilly H; Salles G
    Lancet; 2016 Jun; 387(10036):2402-11. PubMed ID: 27080498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
    Wang BT; Dang HB; Wei YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4.
    Zhen Z; Zhu J; Wang J; Lu S; Sun F; Huang J; Sun X
    Pediatr Hematol Oncol; 2020 Sep; 37(6):489-499. PubMed ID: 32364412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
    Minard-Colin V; Aupérin A; Pillon M; Burke GAA; Barkauskas DA; Wheatley K; Delgado RF; Alexander S; Uyttebroeck A; Bollard CM; Zsiros J; Csoka M; Kazanowska B; Chiang AK; Miles RR; Wotherspoon A; Adamson PC; Vassal G; Patte C; Gross TG; ;
    N Engl J Med; 2020 Jun; 382(23):2207-2219. PubMed ID: 32492302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
    Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience.
    Cairo MS; Sposto R; Perkins SL; Meadows AT; Hoover-Regan ML; Anderson JR; Siegel SE; Lones MA; Tedeschi-Blok N; Kadin ME; Kjeldsberg CR; Wilson JF; Sanger W; Morris E; Krailo MD; Finlay JL
    Br J Haematol; 2003 Feb; 120(4):660-70. PubMed ID: 12588354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.
    Cairo MS; Sposto R; Gerrard M; Auperin A; Goldman SC; Harrison L; Pinkerton R; Raphael M; McCarthy K; Perkins SL; Patte C
    J Clin Oncol; 2012 Feb; 30(4):387-93. PubMed ID: 22215753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol.
    Atra A; Imeson JD; Hobson R; Gerrard M; Hann IM; Eden OB; Carter RL; Pinkerton CR
    Br J Cancer; 2000 Apr; 82(8):1396-402. PubMed ID: 10780517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burkitt lymphoma in children: the Israeli experience.
    Eldar AH; Futerman B; Abrahami G; Attias D; Barak AB; Burstein Y; Dvir R; Gabriel H; Horovitz J; Kapelushnik J; Kaplinsky H; Miskin H; Sthoeger D; Toren A; Vilk-Revel S; Weintraub M; Yaniv I; Linn S; Arush MB
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):428-36. PubMed ID: 19648792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
    Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
    J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.